STERIS delivered strong Q2 2026 results with revenue rising to $1.46 billion and net income reaching $191.9 million. Growth was seen across Healthcare, AST, and Life Sciences segments, with notable increases in service and consumables revenue.

STERIS reported $1.39 billion in revenue and $177.4 million in net income for Q1 2026. EPS was $1.79 and adjusted EPS reached $2.34. All three core segments contributed to top-line growth, led by strong performance in Healthcare and Applied Sterilization Technologies (AST).

STERIS delivered a 4% revenue increase in Q4 2025, supported by solid gains in service and consumables, though Life Sciences saw a decline due to divestiture impacts.

STERIS plc announced strong financial results for its fiscal 2025 third quarter, with total revenue from continuing operations increasing by 6% to $1.4 billion. Net income from continuing operations rose to $173.6 million, and adjusted EPS increased to $2.32. The company also updated its fiscal 2025 outlook, primarily due to shifts in foreign currency rates.

STERIS reported a 7% increase in total revenue from continuing operations, reaching $1.3 billion. The company reiterated its full year outlook for fiscal 2025, with adjusted EPS increasing to $2.14.

STERIS reported an 8% increase in total revenue to $1.3 billion and a 6% growth in constant currency organic revenue. As reported EPS increased to $1.41, while adjusted EPS reached $2.03. The company reiterated its fiscal 2025 outlook, expressing confidence in achieving full-year guidance.

STERIS plc reported a 10% increase in total revenue for Q4 2024, reaching $1.5 billion, driven by strong performance in the Healthcare segment. However, the company experienced a U.S. GAAP net loss of $1.4 million, or ($0.01) per diluted share, due to a pre-tax loss from the reclassification of the Dental segment as discontinued operations and charges related to a targeted restructuring program. Adjusted net income for the quarter was $256.3 million, or $2.58 per diluted share.

STERIS announced a 15% increase in revenue to $1.40 billion for the third quarter of fiscal 2024. As reported diluted earnings per share increased to $1.42, and adjusted earnings per share increased to $2.22. The company updated its fiscal 2024 outlook, expecting revenue to increase by 10-11% and adjusted earnings per diluted share to be in the range of $8.60 to $8.70.

STERIS announced financial results for the second quarter of fiscal year 2024, with revenue increasing by 12% to $1.34 billion and constant currency organic revenue increasing by 8%. The Healthcare segment continued to show momentum, offsetting macro challenges in other segments. The integration of the surgical instrumentation business purchased from BD is progressing as planned.

STERIS plc reported an 11% increase in revenue to $1.28 billion for the first quarter of fiscal 2024, with constant currency organic revenue also increasing by 11%. As reported diluted earnings per share increased to $1.25, and adjusted earnings increased to $2.00. The company has updated its fiscal 2024 outlook to reflect the acquisition of BD surgical instrumentation assets.

STERIS announced strong financial results for its fiscal 2023 fourth quarter, with revenue increasing by 14% to $1.38 billion. Net income was $187.2 million, or $1.88 per share, while adjusted EPS reached $2.30. The company's performance was driven by strong growth in its Healthcare and Applied Sterilization Technologies segments. STERIS provided a positive outlook for fiscal 2024, expecting continued revenue and earnings growth.

STERIS plc reported a 1% increase in revenue to $1.22 billion for the third quarter of fiscal 2023, with a 7% constant currency organic revenue growth. Net earnings were $123.8 million, or $1.24 per share, while adjusted EPS reached $2.02. The company updated its fiscal 2023 outlook, anticipating revenue growth of 6% and adjusted EPS in the range of $8.00 to $8.10.

STERIS plc reported flat revenue at $1.2 billion for Q2 2023, with a net loss of $315.3 million due to a $490.6 million impairment charge in its Dental segment. However, constant currency organic revenue increased by 7%. Adjusted EPS was $1.99, consistent with the previous year.

STERIS announced a 19% increase in revenue, reaching $1.2 billion. Constant currency organic revenue grew by 6%. The company reported an EPS of $1.10 and an adjusted EPS of $1.90.

STERIS announced strong Q4 2022 results with a 39% increase in revenue to $1.2 billion and adjusted EPS of $2.04. The company anticipates another record year of performance in fiscal year 2023, despite ongoing supply chain and inflation challenges.

STERIS announced financial results for its fiscal 2022 third quarter ended December 31, 2021. Revenue increased 49% to $1.2 billion compared to the third quarter of fiscal 2021. Constant currency organic revenue increased 9%. As reported, net income for the third quarter was $143.6 million, or $1.42 per diluted share, compared to $114.5 million, or $1.33 per diluted share, in the third quarter of fiscal 2021.

STERIS plc announced financial results for its fiscal 2022 second quarter ended September 30, 2021. Revenue increased by 58% to $1,197 million compared to the previous year, with constant currency organic revenue growth of 12%. As reported EPS was $0.69, while adjusted EPS reached $1.99. The company is reiterating its fiscal 2022 outlook.

STERIS plc reported a strong first quarter for fiscal year 2022, with revenue increasing by 45% to $968.4 million. Constant currency organic revenue increased by 21%. The company is making good progress with the integration of Cantel Medical and has updated its outlook for fiscal 2022 to reflect better than anticipated performance across the company.

STERIS plc reported a 6% increase in revenue to $873.5 million for the fourth quarter of fiscal year 2021, driven by growth in all three segments. Net income was $87.4 million, or $1.02 per diluted share, while adjusted net income was $140.3 million, or $1.63 per diluted share.

STERIS announced a 4% increase in revenue to $808.9 million and an increase in earnings per diluted share to $1.33 on a U.S. GAAP basis and $1.73 on an adjusted basis for the fiscal 2021 third quarter ended December 31, 2020.

STERIS plc reported a 3% increase in revenue to $756.1 million for the second quarter of fiscal 2021, with a net income of $105.9 million, or $1.23 per diluted share. Adjusted net income increased to $127.3 million, or $1.48 per diluted share. The revenue growth was driven by Life Sciences and Applied Sterilization Technologies, offsetting a decline in Healthcare.

STERIS plc reported a 4% decrease in revenue to $668.9 million, driven by declines in Healthcare and Applied Sterilization Technologies, offset by growth in Life Sciences. Net income increased to $88.2 million, or $1.03 per diluted share, compared to $84.6 million, or $0.99 per diluted share in the previous year.

STERIS plc reported a 7% increase in revenue for the fourth quarter of fiscal 2020, reaching $823.0 million. Net income increased to $123.3 million, or $1.44 per diluted share, compared to $108.7 million, or $1.27 per diluted share, in the same quarter of the previous year. The company experienced growth across all segments and a constant currency organic revenue growth of 8%. Due to the uncertainty of COVID-19, STERIS is not providing guidance for fiscal 2021 at this time.

STERIS plc announced financial results for its fiscal 2020 third quarter ended December 31, 2019. Revenue as reported for the quarter increased 11% to $774.3 million. Net income for the third quarter was $104.9 million, or $1.23 per diluted share. Adjusted net income for the third quarter of fiscal 2020 was $124.0 million, or $1.45 per diluted share.